A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This study is evaluating whether an experimental treatment called GLPG5101 helps to treat non-Hodgkin lymphoma (NHL) and if it is safe to use. This study will be carried out in 2 phases: * The first phase is to see which dose of GLPG5101 works best with the least number of side effects. * In the second phase, all participants will get the best dose of the first phase.
Epistemonikos ID: 39bbbc954bca2ad04fd0aa9f1ff94af1a838a70c
First added on: Sep 01, 2024